NL8803196A - Nieuwe op 17alfa gesubstitueerde 17beta-hydroxy-19-norsteroiden, werkwijze voor de bereiding daarvan, hun toepassing als geneesmiddelen en farmaceutische preparaten die ze bevatten. - Google Patents

Nieuwe op 17alfa gesubstitueerde 17beta-hydroxy-19-norsteroiden, werkwijze voor de bereiding daarvan, hun toepassing als geneesmiddelen en farmaceutische preparaten die ze bevatten. Download PDF

Info

Publication number: NL8803196A
Authority: NL; Netherlands
Prior art keywords: formula; hydroxy; compound; compounds; dimethylamino
Prior art date: 1987-12-30

Application number

NL8803196A

Other languages

English (en)

Dutch (nl)

Original Assignee

Roussel Uclaf

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-12-30

Filing date

1988-12-29

Publication date

1989-07-17

1987-12-30 Priority claimed from FR8718376A external-priority patent/FR2625505B2/fr

1988-12-29 Application filed by Roussel Uclaf filed Critical Roussel Uclaf

1989-07-17 Publication of NL8803196A publication Critical patent/NL8803196A/nl

Links

238000002360 preparation method Methods 0.000 title claims description 12
239000003814 drug Substances 0.000 title claims description 10
238000000034 method Methods 0.000 title claims description 10
239000008194 pharmaceutical composition Substances 0.000 title 1
150000001875 compounds Chemical class 0.000 claims description 60
-1 iodoethenyl group Chemical group 0.000 claims description 48
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 37
239000000047 product Substances 0.000 claims description 29
150000003839 salts Chemical class 0.000 claims description 16
LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 claims description 14
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 12
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 11
239000000825 pharmaceutical preparation Substances 0.000 claims description 10
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 9
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims description 8
229910052794 bromium Inorganic materials 0.000 claims description 7
229910052801 chlorine Inorganic materials 0.000 claims description 7
239000004480 active ingredient Substances 0.000 claims description 6
229910052799 carbon Inorganic materials 0.000 claims description 6
229910052731 fluorine Inorganic materials 0.000 claims description 6
NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 claims description 6
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 6
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 5
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 5
239000000460 chlorine Substances 0.000 claims description 5
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 4
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 4
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Chemical compound [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 claims description 4
239000003795 chemical substances by application Substances 0.000 claims description 4
239000011737 fluorine Substances 0.000 claims description 4
229910052739 hydrogen Inorganic materials 0.000 claims description 4
150000007522 mineralic acids Chemical class 0.000 claims description 4
150000007524 organic acids Chemical class 0.000 claims description 4
235000005985 organic acids Nutrition 0.000 claims description 4
239000002904 solvent Substances 0.000 claims description 4
DBGVGMSCBYYSLD-UHFFFAOYSA-N tributylstannane Chemical compound CCCC[SnH](CCCC)CCCC DBGVGMSCBYYSLD-UHFFFAOYSA-N 0.000 claims description 4
ZXSQEZNORDWBGZ-UHFFFAOYSA-N 1,3-dihydropyrrolo[2,3-b]pyridin-2-one Chemical compound C1=CN=C2NC(=O)CC2=C1 ZXSQEZNORDWBGZ-UHFFFAOYSA-N 0.000 claims description 3
XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 claims description 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
125000004432 carbon atom Chemical group C* 0.000 claims description 3
239000003054 catalyst Substances 0.000 claims description 3
GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 claims description 3
239000001257 hydrogen Substances 0.000 claims description 3
235000003270 potassium fluoride Nutrition 0.000 claims description 3
239000011698 potassium fluoride Substances 0.000 claims description 3
125000004368 propenyl group Chemical group C(=CC)* 0.000 claims description 3
LKZMBDSASOBTPN-UHFFFAOYSA-L silver carbonate Substances [Ag].[O-]C([O-])=O LKZMBDSASOBTPN-UHFFFAOYSA-L 0.000 claims description 3
229910001958 silver carbonate Inorganic materials 0.000 claims description 3
KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 claims description 2
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 2
239000006227 byproduct Substances 0.000 claims description 2
239000003638 chemical reducing agent Substances 0.000 claims description 2
239000012320 chlorinating reagent Substances 0.000 claims description 2
125000001309 chloro group Chemical group Cl* 0.000 claims description 2
125000001153 fluoro group Chemical group F* 0.000 claims description 2
125000000468 ketone group Chemical group 0.000 claims description 2
239000003880 polar aprotic solvent Substances 0.000 claims description 2
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 claims description 2
125000006239 protecting group Chemical group 0.000 claims description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
SQGYOTSLMSWVJD-UHFFFAOYSA-N silver nitrate Substances [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 claims description 2
229910001961 silver nitrate Inorganic materials 0.000 claims description 2
GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 claims description 2
239000000273 veterinary drug Substances 0.000 claims 2
150000001412 amines Chemical class 0.000 claims 1
230000031709 bromination Effects 0.000 claims 1
238000005893 bromination reaction Methods 0.000 claims 1
239000003153 chemical reaction reagent Substances 0.000 claims 1
125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims 1
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 33
239000000243 solution Substances 0.000 description 19
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 16
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
239000000126 substance Substances 0.000 description 12
239000002253 acid Substances 0.000 description 10
229940088597 hormone Drugs 0.000 description 10
239000005556 hormone Substances 0.000 description 10
239000000203 mixture Substances 0.000 description 9
150000007513 acids Chemical class 0.000 description 8
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 8
238000002329 infrared spectrum Methods 0.000 description 8
238000002347 injection Methods 0.000 description 8
239000007924 injection Substances 0.000 description 8
239000000377 silicon dioxide Substances 0.000 description 8
239000012074 organic phase Substances 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
241000282472 Canis lupus familiaris Species 0.000 description 6
241001465754 Metazoa Species 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 5
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
231100000176 abortion Toxicity 0.000 description 5
206010000210 abortion Diseases 0.000 description 5
239000012043 crude product Substances 0.000 description 5
230000000694 effects Effects 0.000 description 5
241000283973 Oryctolagus cuniculus Species 0.000 description 4
239000003862 glucocorticoid Substances 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
239000012071 phase Substances 0.000 description 4
108020003175 receptors Proteins 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
239000000872 buffer Substances 0.000 description 3
229960003957 dexamethasone Drugs 0.000 description 3
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
239000003208 petroleum Substances 0.000 description 3
AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 3
235000019345 sodium thiosulphate Nutrition 0.000 description 3
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
229920002307 Dextran Polymers 0.000 description 2
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
239000013543 active substance Substances 0.000 description 2
239000012298 atmosphere Substances 0.000 description 2
230000037396 body weight Effects 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
238000001816 cooling Methods 0.000 description 2
229940079593 drug Drugs 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000011521 glass Substances 0.000 description 2
238000011534 incubation Methods 0.000 description 2
238000011835 investigation Methods 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
230000000757 progestagenic effect Effects 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
238000010992 reflux Methods 0.000 description 2
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
235000012239 silicon dioxide Nutrition 0.000 description 2
238000001179 sorption measurement Methods 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
229940037128 systemic glucocorticoids Drugs 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
238000002604 ultrasonography Methods 0.000 description 2
210000004291 uterus Anatomy 0.000 description 2
KVQZTSMGPIUHME-HKBOAZHASA-N (8S,13S,14S)-13-but-2-enyl-2,6,7,8,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-one Chemical compound C(=CC)C[C@@]12CCC[C@H]1[C@@H]1CCC3=CC(CCC3=C1CC2)=O KVQZTSMGPIUHME-HKBOAZHASA-N 0.000 description 1
KPZGRMZPZLOPBS-UHFFFAOYSA-N 1,3-dichloro-2,2-bis(chloromethyl)propane Chemical compound ClCC(CCl)(CCl)CCl KPZGRMZPZLOPBS-UHFFFAOYSA-N 0.000 description 1
125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
235000003911 Arachis Nutrition 0.000 description 1
244000105624 Arachis hypogaea Species 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
241000700159 Rattus Species 0.000 description 1
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
210000004100 adrenal gland Anatomy 0.000 description 1
230000032683 aging Effects 0.000 description 1
230000001548 androgenic effect Effects 0.000 description 1
230000002280 anti-androgenic effect Effects 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
238000011888 autopsy Methods 0.000 description 1
TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Inorganic materials [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 1
238000009835 boiling Methods 0.000 description 1
239000012267 brine Substances 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
229940124558 contraceptive agent Drugs 0.000 description 1
239000003433 contraceptive agent Substances 0.000 description 1
210000004246 corpus luteum Anatomy 0.000 description 1
239000006071 cream Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
238000000921 elemental analysis Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
231100000507 endocrine disrupting Toxicity 0.000 description 1
229960005309 estradiol Drugs 0.000 description 1
229930182833 estradiol Natural products 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
150000002222 fluorine compounds Chemical class 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
239000008187 granular material Substances 0.000 description 1
108091008039 hormone receptors Proteins 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
230000036039 immunity Effects 0.000 description 1
206010022437 insomnia Diseases 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
239000012452 mother liquor Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
244000052769 pathogen Species 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
239000000186 progesterone Substances 0.000 description 1
229960003387 progesterone Drugs 0.000 description 1
239000000376 reactant Substances 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
238000002211 ultraviolet spectrum Methods 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
238000005406 washing Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
- C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Diabetes (AREA)
Obesity (AREA)
Hematology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Child & Adolescent Psychology (AREA)
Anesthesiology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Steroid Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NL8803196A 1987-12-30 1988-12-29 Nieuwe op 17alfa gesubstitueerde 17beta-hydroxy-19-norsteroiden, werkwijze voor de bereiding daarvan, hun toepassing als geneesmiddelen en farmaceutische preparaten die ze bevatten. NL8803196A (nl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR8718376A FR2625505B2 (fr)	1981-01-09	1987-12-30	Nouveaux derives steroides substitues en 11beta leur procede de preparation et leur application comme medicaments et les compositions pharmaceutiques les renfermant
FR8718376		1987-12-30

Publications (1)

Publication Number	Publication Date
NL8803196A true NL8803196A (nl)	1989-07-17

Family

ID=9358447

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL8803196A NL8803196A (nl)	1987-12-30	1988-12-29	Nieuwe op 17alfa gesubstitueerde 17beta-hydroxy-19-norsteroiden, werkwijze voor de bereiding daarvan, hun toepassing als geneesmiddelen en farmaceutische preparaten die ze bevatten.

Country Status (14)

Country	Link
US (1)	US5006518A (2)
JP (1)	JP2785023B2 (2)
AT (1)	AT396787B (2)
BE (1)	BE1004905A4 (2)
CA (1)	CA1303025C (2)
CH (1)	CH676852A5 (2)
DE (1)	DE3844408C2 (2)
ES (1)	ES2012197A6 (2)
GB (1)	GB2213484B (2)
GR (1)	GR880100868A (2)
IT (1)	IT1235358B (2)
LU (1)	LU87417A1 (2)
NL (1)	NL8803196A (2)
SE (1)	SE503267C2 (2)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2654337B1 (fr) *	1989-11-15	1994-08-05	Roussel Uclaf	Nouvelles microspheres injectables biodegradables procede de preparation et suspensions injectables les renfermant.
DE4042004A1 (de) *	1990-12-22	1992-06-25	Schering Ag	14(beta)-h-, 14- u. 15-en-11(beta)-aryl-4-estrene
EP0496520A1 (en) *	1991-01-22	1992-07-29	Merck & Co. Inc.	Novel bone acting agents
US6407082B1 (en) *	1996-09-13	2002-06-18	New Life Pharmaceuticals Inc.	Prevention of ovarian cancer by administration of a vitamin D compound
JP3862295B2 (ja) *	1993-09-30	2006-12-27	独立行政法人理化学研究所	抗肥満剤
US5639598A (en) *	1994-05-19	1997-06-17	The Trustees Of The University Of Pennsylvania	Method and kit for identification of antiviral agents capable of abrogating HIV Vpr-Rip-1 binding interactions
US5780220A (en) *	1994-05-19	1998-07-14	Trustees Of The University Of Pennsylvania	Methods and compositions for inhibiting HIV replication
ATE156836T1 (de) *	1994-05-19	1997-08-15	Akzo Nobel Nv	11,21-bisphenyl-19-nor-pregnan derivate
US6511970B1 (en)	1996-09-13	2003-01-28	New Life Pharmaceuticals Inc.	Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
US6765002B2 (en)	2000-03-21	2004-07-20	Gustavo Rodriguez	Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
US6028064A (en) *	1996-09-13	2000-02-22	New Life Pharmaceuticals Inc.	Prevention of ovarian cancer by administration of progestin products
US6034074A (en)	1996-09-13	2000-03-07	New Life Pharmaceuticals Inc.	Prevention of ovarian cancer by administration of a Vitamin D compound
DE19706061A1 (de)	1997-02-07	1998-08-13	Schering Ag	Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
US20010044431A1 (en) *	2000-03-21	2001-11-22	Rodriguez Gustavo C.	Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
JP2001301596A (ja)	2000-04-19	2001-10-31	Sumitomo Denko Brake Systems Kk	車両用液圧ブレーキシステムの制御方法
WO2008137050A2 (en) *	2007-05-01	2008-11-13	Sicor Inc.	A process for preparing drospirenone and intermediate thereof
PL2576582T3 (pl)	2010-05-26	2020-06-29	Corcept Therapeutics, Inc.	Leczenie dystrofii mięśniowej
WO2016140867A1 (en)	2015-03-02	2016-09-09	Corcept Therapeutics, Inc.	Use of glucocorticoid receptor antagonist and somatostatin analogues to treat acth-secreting tumors
US10610534B2 (en)	2015-03-30	2020-04-07	Corcept Therapeutics, Inc.	Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency
KR20180052120A (ko)	2015-08-13	2018-05-17	코어셉트 쎄라퓨틱스, 잉크.	Acth-의존성 쿠싱 증후군을 감별 진단하는 방법
WO2017112902A1 (en)	2015-12-23	2017-06-29	Oric Pharmaceuticals, Inc.	Inhibitors of glucocorticoid receptor
US11110103B2 (en)	2015-12-23	2021-09-07	Oric Pharmaceuticals, Inc.	Inhibitors of glucocorticoid receptor
US11208432B2 (en)	2015-12-23	2021-12-28	Oric Pharmaceuticals, Inc.	Inhibitors of glucocorticoid receptor
KR102197526B1 (ko)	2016-01-19	2020-12-31	코어셉트 쎄라퓨틱스 인코포레이티드	이소성 쿠싱 증후군의 감별 진단
PL3523315T3 (pl)	2016-10-07	2021-10-18	Oric Pharmaceuticals, Inc.	Inhibitor receptora glukokortykoidowego
SG11201908790PA (en)	2017-03-31	2019-10-30	Corcept Therapeutics Inc	Glucocorticoid receptor modulators to treat cervical cancer
MX393313B (es)	2017-06-20	2025-03-24	Corcept Therapeutics Inc	Metodos de tratamiento de tumores neuroepiteliales usando moduladores selectivos del receptor de glucocorticoide.
JP2024500748A (ja)	2020-12-18	2024-01-10	インスティルバイオ（ユーケイ）リミテッド	腫瘍浸潤リンパ球の処理

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2377418A1 (fr) *	1977-01-13	1978-08-11	Roussel Uclaf	Nouveaux derives steroides 4,9-dieniques 11b-substitues, leur procede de preparation et leur application comme medicaments
ATE23167T1 (de) *	1981-01-09	1986-11-15	Roussel Uclaf	In stellung 11 substituierte steroidzwischenprodukte und verfahren zu ihrer herstellung.
ZA8231B (en) *	1981-01-09	1982-11-24	Roussel Uclaf	New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
FR2528434B1 (fr) *	1982-06-11	1985-07-19	Roussel Uclaf	Nouveaux 19-nor steroides substitues en 11b et eventuellement en 2, leur procede de preparation et leur application comme medicament
EP0116974B1 (de) *	1983-02-18	1986-10-29	Schering Aktiengesellschaft	11-Beta-Aryl-Estradiene, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Präparate
FR2549067B1 (fr) *	1983-06-14	1985-12-27	Roussel Uclaf	Derives estradieniques radioactifs marques au tritium, leur procede de preparation et leur application pour l'etude et le dosage radio-immunologique de steroides dans les fluides biologiques
ES533260A0 (es) *	1983-06-15	1985-02-01	Schering Ag	Procedimiento para la preparacion de 13a-alquilgonanos
US4780461A (en) *	1983-06-15	1988-10-25	Schering Aktiengesellschaft	13α-alkyl-gonanes, their production, and pharmaceutical preparations containing same
DE3347126A1 (de) *	1983-12-22	1985-07-11	Schering AG, 1000 Berlin und 4709 Bergkamen	11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
FR2566779B2 (fr) *	1984-06-29	1987-03-06	Roussel Uclaf	Nouveaux derives steroides substitues en 11b, leur procede de preparation et leur application comme medicaments
DE3506785A1 (de) *	1985-02-22	1986-08-28	Schering AG, Berlin und Bergkamen, 1000 Berlin	11ss-n,n-dimethylaminophenyl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3619413C2 (de) *	1986-06-10	2000-04-06	Schering Ag	9alpha, 10alpha-Methylen-Estrene, deren Herstellung und diese enthaltende pharmazeutische Präparate
DE3625315A1 (de) *	1986-07-25	1988-01-28	Schering Ag	11ss-(4-isopropenylphenyl)-estra-4,9-diene, deren herstellung und diese enthaltende pharmazeutische praeparate
US4774236A (en) *	1986-09-17	1988-09-27	Research Triangle Institute	17α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and pharmaceutical compositions containing them
IE60780B1 (en) *	1987-01-23	1994-08-10	Akzo Nv	New 11-aryl steroid derivatives

1988
- 1988-12-28 JP JP63329538A patent/JP2785023B2/ja not_active Expired - Fee Related
- 1988-12-28 BE BE8801441A patent/BE1004905A4/fr not_active IP Right Cessation
- 1988-12-29 SE SE8804692A patent/SE503267C2/sv not_active IP Right Cessation
- 1988-12-29 GR GR880100868A patent/GR880100868A/el unknown
- 1988-12-29 LU LU87417A patent/LU87417A1/fr unknown
- 1988-12-29 ES ES8804011A patent/ES2012197A6/es not_active Expired - Fee Related
- 1988-12-29 NL NL8803196A patent/NL8803196A/nl not_active Application Discontinuation
- 1988-12-29 CH CH4860/88A patent/CH676852A5/fr not_active IP Right Cessation
- 1988-12-29 IT IT8848730A patent/IT1235358B/it active
- 1988-12-29 AT AT0318788A patent/AT396787B/de not_active IP Right Cessation
- 1988-12-29 CA CA000587227A patent/CA1303025C/fr not_active Expired - Lifetime
- 1988-12-30 GB GB8830380A patent/GB2213484B/en not_active Expired - Lifetime
- 1988-12-30 DE DE3844408A patent/DE3844408C2/de not_active Expired - Lifetime
- 1988-12-30 US US07/292,475 patent/US5006518A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
JP2785023B2 (ja)	1998-08-13
IT1235358B (it)	1992-06-30
US5006518A (en)	1991-04-09
LU87417A1 (fr)	1989-06-14
SE503267C2 (sv)	1996-04-29
GB8830380D0 (en)	1989-03-01
ES2012197A6 (es)	1990-03-01
IT8848730A0 (it)	1988-12-29
CH676852A5 (2)	1991-03-15
SE8804692D0 (sv)	1988-12-29
AT396787B (de)	1993-11-25
CA1303025C (fr)	1992-06-09
BE1004905A4 (fr)	1993-02-23
SE8804692L (sv)	1989-07-01
DE3844408C2 (de)	2001-07-26
GB2213484A (en)	1989-08-16
GB2213484B (en)	1991-10-09
JPH01213296A (ja)	1989-08-28
DE3844408A1 (de)	1989-07-13
ATA318788A (de)	1993-04-15
GR880100868A (el)	1994-03-31

Legal Events

Date	Code	Title	Description
1996-05-01	BA	A request for search or an international-type search has been filed
1996-08-01	BB	A search report has been drawn up
1996-12-02	BC	A request for examination has been filed
2000-08-01	CNR	Transfer of rights (patent application after its laying open for public inspection)	Free format text: HOECHST ROUSSEL VET S.A.
2001-09-03	BV	The patent application has lapsed

Publication	Publication Date	Title
JP2785023B2 (ja)	1998-08-13	１７α位置を置換された１７β―ＯＨ―１９―ノルステロイドの新誘導体、その製造方法、その薬剤としての使用及びそれを含有する製薬組成物
KR930005993B1 (ko)	1993-07-01	위치 10에 치환된 스테로이드의 제조방법
AU699701B2 (en)	1998-12-10	Estra-1,3,5(10)-triene derivatives, processes for their preparation and pharmaceutical compositions containing these compounds
CZ278094A3 (en)	1995-02-15	Competitive progesteron antagonist and use thereo competitive progesteron antagonist and use thereof f
WO2011009529A2 (de)	2011-01-27	17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-derivate, verfahren zu ihrer herstellung und ihre verwendung zur behandlung von krankheiten
DE4332284A1 (de)	1995-03-23	Neue 11-Benzaldoxim-17beta-methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
EP0299913A1 (de)	1989-01-18	11Beta-Phenyl-4,9,15-Estratriene, deren Herstellung und diese enthaltende pharmazeutische Präparate
EP1525215B1 (de)	2006-09-06	Progesteronrezeptormodulatoren mit erhöhter antigonadotroper aktivität für die weibliche fertilitätskontrolle und hormonersatztherapie
DK145610B (da)	1982-12-27	3-oximer af 17alfa-ethynyl-19-nortestosteronestere til anvendelse til undertrykkelse af fertilitet
JP3026997B2 (ja)	2000-03-27	１９―ノルステロイドから導かれる基が芳香族核上に置換している新規なω―フェニルアミノアルカン酸及びそれらの塩類、これらの製造法、この製造法の新規な中間体、これらの薬剤としての使用並びにこれらを含有する組成物
JP4392066B2 (ja)	2009-12-24	避妊活性及び抗骨粗鬆症活性を有するステロイド化合物
CA2384184C (en)	2008-07-08	17.beta.-acyl-17.alpha.-propynyl-11.beta.-(cyclic amino) aryl steroids and their derivatives having antagonist hormonal properties
JP4002438B2 (ja)	2007-10-31	ステロイド類、それらの調製、それらの薬学的組成物およびこの化合物の使用
JPS6355488B2 (2)	1988-11-02
EP1061928A2 (en)	2000-12-27	New contraceptive kit
JP2001507010A (ja)	2001-05-29	１１位が置換されたステロイド、それらの製造方法、それらの薬剤としての用途及びそれらを含有する製薬組成物
DE60026608T2 (de)	2006-12-28	3-methylen steroid derivate zur behandlung von autoimmunerkrankungen
US5866559A (en)	1999-02-02	17α-cyanomethylestra-4,9-dien derivatives and pharmaceutical compositions containing same
DE1951990C3 (de)	1973-09-27	3-Cyciopentyloxy-13-äthyl-17alphaäthinylgona-3,5-dien-17beta-ol und dessen Acylderivate
DE3644358A1 (de)	1987-06-25	10(beta)-alkynyl-4,9(11)-oestradien-derivate, verfahren zu deren herstellung und arzneimittel, welche diese enthalten
FR2625505A2 (fr)	1989-07-07	Nouveaux derives steroides substitues en 11beta leur procede de preparation et leur application comme medicaments et les compositions pharmaceutiques les renfermant
AT272535B (de)	1969-07-10	Verfahren zur Herstellung von neuen 6-Fluormethyl-3-oxo-4,6-dien-steroiden der Pregnanreihe
US3409722A (en)	1968-11-05	Novel 16-oximidomethylene-gonanes
DE1793422C3 (de)	1977-09-29	4,6-Dichlor-4,6-östradiene, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel, sowie rac-u.nat. 6-Chlor- lTbeta-acetoxy-ie-methyl-17 a-äthinyl-4,6-östradien-3-on als Ausgangsverbindungen
DE3644301A1 (de)	1987-07-02	10ss-halo-alkynyloestren-derivate, verfahren zu deren herstellung und arzneimittel, welche diese enthalten